Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Liver cancer, adult primary
Stage/Subtype:  stage C adult primary liver cancer (BCLC)
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 52 for your search:
Start Over
Sorafenib Tosylate in Treating Patients with Advanced Liver Cancer and Hepatitis C Infection
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-213, NCI-2013-01103, NCT01849588
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TS-103, NCI-2012-01029, NCT01556490
Sorafenib Tosylate with or without Stereotactic Body Radiation Therapy in Treating Patients with Liver Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 1112, NCI-2012-02057, NCT01730937
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ARQ197-A-U303, NCI-2013-00021, NCT01755767
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 15982, NCI-2013-01156, 2012-003649-14, NCT01774344
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: XL184-309, NCI-2013-02092, NCT01908426
TRC105 and Sorafenib Tosylate in Treating Patients with Liver Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0102, NCI-2013-01477, 110102, 339029, P10766, NCT01306058
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients with Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: N1153, NCI-2012-00095, CDR0000720022, NCCTG-N1153, NCT01497444
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-132-01, NCI-2014-00136, NCT01631552
Ascorbic Acid and Sorafenib Tosylate in Treating Patients with Metastatic Liver Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: 12D.424, NCI-2014-01892, 2012-40, NCT01754987
Tivozanib in Treating Patients with Liver Cancer That is Metastatic or Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 229112, NCI-2013-00756, NCT01835223
A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15246, NCI-2014-02649, I4C-MC-JTBF, NCT02082210
Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TKM-HCC-001, NCI-2015-00970, NCT02191878
A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBIHCC-103, NCI-2014-02447, NCT02279719
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 11-003311, NCI-2012-00911, NCT01624285
Temsirolimus and Sorafenib Tosylate in Treating Patients With Stage II-IV Liver Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 85
Trial IDs: 124511, NCI-2012-02021, NCT01687673
Sorafenib Tosylate and Combination Chemotherapy in Treating Patients with Advanced Liver Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-218, NCI-2013-00627, NCT01775501
Sorafenib Tosylate and Doxorubicin Hydrochloride in Treating Patients with Advanced Liver Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-259, NCI-2013-00867, NCT01840592
Doxorubicin-Eluting Beads in Treating Patients with Liver Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J1306, NCI-2014-00341, CIR00005192, DEBDOX-M1, NA_00077927, NCT02007954
Ponatinib Hydrochloride in Treating Patients with Advanced Biliary Cancer with FGFR2 Fusions
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1345, NCI-2014-02075, NCT02265341
Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: NU 08I5, NCI-2009-01122, STU00007062, NCT00858429
Oncolytic HSV-1 rRp450 in Treating Patients with Primary Liver Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 09-042, NCI-2010-01930, NCT01071941
Start Over